current glp 1 drugs New GLP-1 Guidelines for Type 2 Diabetes in 2025 Comparing Ozempic, Wegovy and Other

GLP-1 (glucagon-like peptide 1) is a receptor agonist, a class of drugs originally designed to treat type 2 diabetes, with brand names such as Ozempic, Wegovy, and Mounjaro

for example, caution must be taken in the case of a patient suffering from gastroparesis since the activation of the GLP-1 receptor through the administration of an agonist leads to a decrease in gastric emptying, which induces an exacerbation of symptoms and even the discovery of the disease after drug intake

We extracted the culture medium after cell culture for ELISA detection

10.1007/s10620-012-2353-7 [DOI] [PubMed] [Google Scholar] 49.Karl T, Hoffmann T, Pabst R, von Hrsten S

this suggests a rapid phase of GLP-1 secretion caused by direct stimulation of L-cells in the upper GI tract and a second phase potentially caused by signals from the upper gut reaching the lower small and perhaps even the large intestine [323,324]